1. Scrip
  2. >>Therapy Areas

What to look out for at the Alzheimer's Association International Conference

 
• By Alexandra Shimmings

New data for Roche's crenezumab and updates on novel strategies are expected to provide most interest at the upcoming Alzheimer's Association International Conference (AAIC) in Copenhagen from 12-17 July. The meeting will also hear on the progress of about trials looking at the prevention of the disease, say analysts at BioMedTracker.

New data for Roche's crenezumab and updates on novel strategies are expected to provide most interest at the upcoming Alzheimer's Association International Conference (AAIC) in Copenhagen from 12-17 July. The meeting will also hear on the progress of about trials looking at the prevention of the disease, say analysts at BioMedTracker.

Data are due from two studies of Roche's crenezumab: the Phase II ABBY study and the Phase II BLAZE study to evaluate the impact of the product on brain amyloid load and related biomarkers in patients with mild to moderate Alzheimer's disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.